[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epoetin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epoetin":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100643343","phase-2-luspatercept-vs-epoetin-in-treating-poor-erythroid-engraftment-for-hematological-malignancies-100643343",false,"NCT07636486","Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Inclusion Criteria:\n\n* 18-65 years\n* Hematologic malignancies\n* Poor erythroid engraftment after the first allo-HSCT\n* Complete remission post-transplantation\n* Eastern Cooperative Oncology Group performance status of 0-2\n* Epoetin-naive\n* Endogenous serum erythropoietin concentration \\\u003C500 U\u002FL\n\nExclusion Criteria:\n\n* Life expectancy shorter than 30 days post-transplantation\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)","ALL","18 Years","65 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.",[28,29,30,31],"Luspatercept","Epoetin","Poor Erythroid Engraftment","Hematological Malignancies","NOT_YET_RECRUITING","2026-06-04",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":21},"2026-06-15",{"date":40,"type":21},"2030-12-31",{"name":42,"class":43},"Nanfang Hospital, Southern Medical University","OTHER"]